MK-5108, a Highly Selective Aurora-A Kinase Inhibitor, Shows Antitumor Activity Alone and in Combination with Docetaxel
- 1 January 2010
- journal article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 9 (1), 157-166
- https://doi.org/10.1158/1535-7163.mct-09-0609
Abstract
Aurora-A kinase is a one of the key regulators during mitosis progression. Aurora-A kinase is a potential target for anticancer therapies because overexpression of Aurora-A, which is frequently observed in some human cancers, results in aberrant mitosis leading to chromosomal instability and possibly tumorigenesis. MK-5108 is a novel small molecule with potent inhibitory activity against Aurora-A kinase. Although most of the Aurora-kinase inhibitors target both Aurora-A and Aurora-B, MK-5108 specifically inhibited Aurora-A kinase in a panel of protein kinase assays. Inhibition of Aurora-A by MK-5108 in cultured cells induced cell cycle arrest at the G2-M phase in flow cytometry analysis. The effect was confirmed by the accumulation of cells with expression of phosphorylated Histone H3 and inhibition of Aurora-A autophosphorylation by immunostaining assays. MK-5108 also induced phosphorylated Histone H3 in skin and xenograft tumor tissues in a nude rat xenograft model. MK-5108 inhibited growth of human tumor cell lines in culture and in different xenograft models. Furthermore, the combination of MK-5108 and docetaxel showed enhanced antitumor activities compared with control and docetaxel alone–treated animals without exacerbating the adverse effects of docetaxel. MK-5108 is currently tested in clinical trials and offers a new therapeutic approach to combat human cancers as a single agent or in combination with existing taxane therapies. Mol Cancer Ther; 9(1); 157–66Keywords
Other Versions
This publication has 33 references indexed in Scilit:
- Aurora kinase A inhibition and paclitaxel as targeted combination therapy for head and neck squamous cell carcinomaHead & Neck, 2008
- Aurora kinase inhibitors synergize with paclitaxel to induce apoptosis in ovarian cancer cellsJournal of Translational Medicine, 2008
- Targeting Aurora Kinase with MK-0457 Inhibits Ovarian Cancer GrowthClinical Cancer Research, 2008
- Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinaseProceedings of the National Academy of Sciences of the United States of America, 2007
- Small Interfering RNA Screens Reveal Enhanced Cisplatin Cytotoxicity in Tumor Cells Having both BRCA Network and TP53 DisruptionsMolecular and Cellular Biology, 2006
- Predictive factors for response to docetaxel in human breast cancersCancer Science, 2006
- The chromosomal passenger complex: guiding Aurora-B through mitosisThe Journal of cell biology, 2006
- Mitotic requirement for aurora A kinase is bypassed in the absence of aurora B kinaseFEBS Letters, 2005
- Aurora-A and an Interacting Activator, the LIM Protein Ajuba, Are Required for Mitotic Commitment in Human CellsCell, 2003
- A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancersThe EMBO Journal, 1998